Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) insider Benjamin T. Dake sold 10,284 shares of Aerovate Therapeutics stock in a transaction that occurred on Friday, January 6th. The stock was sold at an average price of $25.98, for a total value of $267,178.32. Following the completion of the sale, the insider now directly owns 1,609 shares in the company, valued at approximately $41,801.82. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Benjamin T. Dake also recently made the following trade(s):
Get
Aerovate Therapeutics alerts:
- On Friday, November 11th, Benjamin T. Dake sold 6,198 shares of Aerovate Therapeutics stock. The stock was sold at an average price of $20.69, for a total value of $128,236.62.
- On Tuesday, November 8th, Benjamin T. Dake sold 8,373 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $18.09, for a total value of $151,467.57.
- On Monday, October 17th, Benjamin T. Dake sold 4,185 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $20.16, for a total value of $84,369.60.
- On Friday, October 14th, Benjamin T. Dake sold 110 shares of Aerovate Therapeutics stock. The shares were sold at an average price of $20.05, for a total value of $2,205.50.
Aerovate Therapeutics Stock Down 2.7 %
Shares of Aerovate Therapeutics stock opened at $25.30 on Thursday. The stock's fifty day moving average is $22.68 and its two-hundred day moving average is $20.16. The company has a market capitalization of $617.57 million, a PE ratio of -16.11 and a beta of 0.80. Aerovate Therapeutics, Inc. has a 52 week low of $7.74 and a 52 week high of $30.79.
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) last announced its quarterly earnings data on Monday, November 14th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.50) by ($0.06). As a group, research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.07 earnings per share for the current year.
Institutional Investors Weigh In On Aerovate Therapeutics
Hedge funds have recently made changes to their positions in the company. Parkwood LLC purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $32,000. Russell Investments Group Ltd. purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $32,000. Chicago Partners Investment Group LLC purchased a new stake in shares of Aerovate Therapeutics in the 2nd quarter worth $226,000. Amalgamated Bank purchased a new stake in shares of Aerovate Therapeutics in the 1st quarter worth $27,000. Finally, Citadel Advisors LLC lifted its holdings in shares of Aerovate Therapeutics by 1.5% in the 3rd quarter. Citadel Advisors LLC now owns 1,615,578 shares of the company's stock worth $26,786,000 after buying an additional 23,569 shares during the period.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on AVTE shares. BTIG Research raised Aerovate Therapeutics from a "neutral" rating to a "buy" rating and set a $27.00 target price on the stock in a research report on Tuesday, December 6th. Wedbush boosted their target price on Aerovate Therapeutics from $27.00 to $54.00 in a research report on Monday, December 12th.
Aerovate Therapeutics Company Profile
(Get Rating)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
- Get a free copy of the StockNews.com research report on Aerovate Therapeutics (AVTE)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
